<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37675114</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>BAFF system expression in double negative 2, activated na&#xef;ve and activated memory B cells in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1235937</StartPage><MedlinePgn>1235937</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1235937</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1235937</ELocationID><Abstract><AbstractText Label="INTRODUCTION">B cell activating factor (BAFF) has an important role in normal B cell development. The aberrant expression of BAFF is related with the autoimmune diseases development like Systemic Lupus Erythematosus (SLE) for promoting self-reactive B cells survival. BAFF functions are exerted through its receptors BAFF-R (BR3), transmembrane activator calcium modulator and cyclophilin ligand interactor (TACI) and B cell maturation antigen (BCMA) that are reported to have differential expression on B cells in SLE. Recently, atypical B cells that express CD11c have been associated with SLE because they are prone to develop into antibody-secreting cells, however the relationship with BAFF remains unclear. This study aims to analyze the BAFF system expression on CXCR5<sup>-</sup> CD11c<sup>+</sup> atypical B cell subsets double negative 2 (DN2), activated na&#xef;ve (aNAV), switched memory (SWM) and unswitched memory (USM) B cells.</AbstractText><AbstractText Label="METHODS">Forty-five SLE patients and 15 healthy subjects (HS) were included. Flow cytometry was used to evaluate the expression of the receptors in the B cell subpopulations. Enzyme-linked immunosorbent assay (ELISA) was performed to quantify the soluble levels of BAFF (sBAFF) and IL-21.</AbstractText><AbstractText Label="RESULTS">We found increased frequency of CXCR5<sup>-</sup> CD11c<sup>+</sup> atypical B cell subpopulations DN2, aNAV, SWM and USM B cells in SLE patients compared to HS. SLE patients had increased expression of membrane BAFF (mBAFF) and BCMA receptor in classic B cell subsets (DN, NAV, SWM and USM). Also, the CXCR5<sup>+</sup> CD11c<sup>-</sup> DN1, resting na&#xef;ve (rNAV), SWM and USM B cell subsets showed higher mBAFF expression in SLE. CXCR5<sup>-</sup> CD11c<sup>+</sup> atypical B cell subpopulations DN2, SWM and USM B cells showed strong correlations with the expression of BAFF receptors. The atypical B cells DN2 in SLE showed significant decreased expression of TACI, which correlated with higher IL-21 levels. Also, lower expression of TACI in atypical B cell DN2 was associated with high disease activity.</AbstractText><AbstractText Label="DISCUSSION">These results suggest a participation of the BAFF system in CXCR5<sup>-</sup> CD11c<sup>+</sup> atypical B cell subsets in SLE patients. Decreased TACI expression on atypical B cells DN2 correlated with high disease activity in SLE patients supporting the immunoregulatory role of TACI in autoimmunity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 &#xc1;lvarez G&#xf3;mez, Salazar-Camarena, Rom&#xe1;n-Fern&#xe1;ndez, Ortiz-Lazareno, Cruz, Mu&#xf1;oz-Valle, Mar&#xed;n-Rosales, Espinoza-Garc&#xed;a, Sagrero-Fabela and Palafox-S&#xe1;nchez.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#xc1;lvarez G&#xf3;mez</LastName><ForeName>Jhonatan Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Doctorado en Ciencias en Biolog&#xed;a Molecular en Medicina (DCBMM), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salazar-Camarena</LastName><ForeName>Diana Celeste</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Grupo de Inmunolog&#xed;a Molecular, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rom&#xe1;n-Fern&#xe1;ndez</LastName><ForeName>Ilce Valeria</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n en Ciencias Biom&#xe9;dicas (IICB), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz-Lazareno</LastName><ForeName>Pablo C&#xe9;sar</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Divisi&#xf3;n de Inmunolog&#xed;a, Centro de Investigaci&#xf3;n Biom&#xe9;dica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n en Ciencias Biom&#xe9;dicas (IICB), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz-Valle</LastName><ForeName>Jos&#xe9; Francisco</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n en Ciencias Biom&#xe9;dicas (IICB), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mar&#xed;n-Rosales</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grupo de Inmunolog&#xed;a Molecular, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital General de Occidente, Secretar&#xed;a de Salud Jalisco, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinoza-Garc&#xed;a</LastName><ForeName>Noem&#xed;</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Doctorado en Ciencias en Biolog&#xed;a Molecular en Medicina (DCBMM), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagrero-Fabela</LastName><ForeName>Nefertari</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Doctorado en Ciencias Biom&#xe9;dicas (DCB), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palafox-S&#xe1;nchez</LastName><ForeName>Claudia Azucena</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Grupo de Inmunolog&#xed;a Molecular, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n en Ciencias Biom&#xe9;dicas (IICB), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053264">B-Cell Activating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053301">B-Cell Maturation Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091245" MajorTopicYN="N">Memory B Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053264" MajorTopicYN="N">B-Cell Activating Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053301" MajorTopicYN="N">B-Cell Maturation Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BAFF system expression</Keyword><Keyword MajorTopicYN="N">DN2</Keyword><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">aNAV</Keyword><Keyword MajorTopicYN="N">atypical B cells</Keyword><Keyword MajorTopicYN="N">memory B cells</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37675114</ArticleId><ArticleId IdType="pmc">PMC10478082</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1235937</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. . Systemic lupus erythematosus. Nat Rev Dis Primers (2016) 2:16039. doi:&#xa0;10.1038/nrdp.2016.39</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. . Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheumatism (2008) 58(8):2453&#x2013;9. doi:&#xa0;10.1002/art.23678</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23678</ArticleId><ArticleId IdType="pubmed">18668552</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy EM, Lee RZ, N&#xed; Gabhann J, Smith S, Cunnane G, Doran MF, et al. . Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. Rheumatology (2013) 52(7):1279&#x2013;84. doi:&#xa0;10.1093/rheumatology/ket120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket120</ArticleId><ArticleId IdType="pubmed">23479724</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed;n-Rosales M, Cruz A, Salazar-Camarena DC, Santill&#xe1;n-L&#xf3;pez E, Espinoza-Garc&#xed;a N, Mu&#xf1;oz-Valle JF, et al. . High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C&lt;T polymorphism in TNFSF13B gene. Clin Exp Med (2019) 19(2):183&#x2013;90. doi:&#xa0;10.1007/s10238-019-00549-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-019-00549-8</ArticleId><ArticleId IdType="pubmed">30747361</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol (2009) 9(7):491&#x2013;502. doi:&#xa0;10.1038/nri2572</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2572</ArticleId><ArticleId IdType="pubmed">19521398</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, Oregon-Romero E, Machado-Contreras JR, Mu&#xf1;oz-Valle JF, et al. . Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus (2016) 25(6):582&#x2013;92. doi:&#xa0;10.1177/0961203315608254</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315608254</ArticleId><ArticleId IdType="pubmed">26424128</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al. . Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity (2018) 49(4):725&#x2013;739.e6. doi:&#xa0;10.1016/j.immuni.2018.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.08.015</ArticleId><ArticleId IdType="pmc">PMC6217820</ArticleId><ArticleId IdType="pubmed">30314758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wang J, Kumar V, Karnell JL, Naiman B, Gross PS, et al. . IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE. Nat Commun (2018) 9(1):1758&#x2013;8. doi:&#xa0;10.1038/s41467-018-03750-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03750-7</ArticleId><ArticleId IdType="pmc">PMC5931508</ArticleId><ArticleId IdType="pubmed">29717110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, et al. . IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol (2005) 175(12):7867&#x2013;79. doi:&#xa0;10.4049/jimmunol.175.12.7867</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.12.7867</ArticleId><ArticleId IdType="pubmed">16339522</ArticleId></ArticleIdList></Reference><Reference><Citation>Naradikian MS, Myles A, Beiting DP, Roberts KJ, Dawson L, Herati RS, et al. . Cutting edge: IL-4, IL-21, and IFN-&#x3b3; Interact to govern T-bet and CD11c expression in TLR-activated B cells. J Immunol (2016) 197(4):1023&#x2013;8. doi:&#xa0;10.4049/jimmunol.1600522</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600522</ArticleId><ArticleId IdType="pmc">PMC4975960</ArticleId><ArticleId IdType="pubmed">27430719</ArticleId></ArticleIdList></Reference><Reference><Citation>Levack RC, Newell KL, Popescu M, Cabrera-Martinez B, Winslow GM. CD11c + T-bet + B cells require IL-21 and IFN-&#x3b3; from type 1 T follicular helper cells and intrinsic Bcl-6 expression but develop normally in the absence of T-bet. J Immunol (2020) 205(4):1050&#x2013;8. doi:&#xa0;10.4049/jimmunol.2000206</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000206</ArticleId><ArticleId IdType="pmc">PMC7556359</ArticleId><ArticleId IdType="pubmed">32680956</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau D, Lan LY, Andrews SF, Henry C, Rojas KT, Neu KE, et al. . Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation. Sci Immunol (2017) 2(7):eaai8153. doi:&#xa0;10.1126/sciimmunol.aai8153</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aai8153</ArticleId><ArticleId IdType="pmc">PMC5896567</ArticleId><ArticleId IdType="pubmed">28783670</ArticleId></ArticleIdList></Reference><Reference><Citation>Torigoe M, Iwata S, Nakayamada S, Sakata K, Zhang M, Hajime M, et al. . Metabolic reprogramming commits differentiation of human CD27+IgD+ B cells to plasmablasts or CD27&#x2013;IgD&#x2013; cells. J Immunol (2017) 199(2):425&#x2013;34. doi:&#xa0;10.4049/jimmunol.1601908</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601908</ArticleId><ArticleId IdType="pubmed">28626065</ArticleId></ArticleIdList></Reference><Reference><Citation>Rincon-Arevalo H, Wiedemann A, Stefanski AL, Lettau M, Szelinski F, Fuchs S, et al. . Deep phenotyping of CD11c+ B cells in systemic autoimmunity and controls. Front Immunol (2021) 12:635615. doi:&#xa0;10.3389/fimmu.2021.635615</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.635615</ArticleId><ArticleId IdType="pmc">PMC7994903</ArticleId><ArticleId IdType="pubmed">33777025</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtado C, Rojas-Gualdr&#xf3;n DF, Urrego R, Cashman K, V&#xe1;squez-Trespalacios EM, D&#xed;az-Coronado JC, et al. . Altered B cell phenotype and CD27+ memory B cells are associated with clinical features and environmental exposure in Colombian systemic lupus erythematosus patients. Front Med (2022) 9:950452(September). doi:&#xa0;10.3389/fmed.2022.950452</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.950452</ArticleId><ArticleId IdType="pmc">PMC9485945</ArticleId><ArticleId IdType="pubmed">36148466</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y, O'Neill P, Naradikian MS, Scholz JL, Cancro MP. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood (2011) 118(5):1294&#x2013;304. doi:&#xa0;10.1182/blood-2011-01-330530</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-01-330530</ArticleId><ArticleId IdType="pmc">PMC3152496</ArticleId><ArticleId IdType="pubmed">21562046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsk&#xf6;ld D, Parodis I, Lakshmikanth T, Sippl N, Khademi M, Chen Y, et al. . B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine (2019) 40:517&#x2013;27. doi:&#xa0;10.1016/j.ebiom.2018.12.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.12.035</ArticleId><ArticleId IdType="pmc">PMC6412067</ArticleId><ArticleId IdType="pubmed">30593436</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. . 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheumatic Dis (2019) 78(9):1151&#x2013;9. doi:&#xa0;10.1136/annrheumdis-2018-214819</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzm&#xe1;n J, Cardiel MH, Arce-Salinas A, S&#xe1;nchez-Guerrero J, Alarc&#xf3;n-Segovia D. &#x2018;Measurement of disease activity in systemic lupus erythematosus. Prospective validation 3 Clin indices&#x2019; J Rheumatol (1992) 19(10):1551&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1464867</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar-Camarena DC, Ort&#xed;z-Lazareno P, Mar&#xed;n-Rosales M, Cruz A, Mu&#xf1;oz-Valle F, Tapia-Llanos R, et al. . BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus. Cytokine (2019) 114(May):115&#x2013;27. doi:&#xa0;10.1016/j.cyto.2018.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2018.11.008</ArticleId><ArticleId IdType="pubmed">30467093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Wang YF, Hu FL, Lu FA, Wu T, Feng YL, et al. . Dysfunction of CD27+IgD+ B cells correlates with aggravated systemic lupus erythematosus. Clin Rheumatol (2022) 41(5):1551&#x2013;9. doi:&#xa0;10.1007/s10067-022-06051-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06051-z</ArticleId><ArticleId IdType="pubmed">35032222</ArticleId></ArticleIdList></Reference><Reference><Citation>Holla P, Dizon B, Ambegaonkar AA, Rogel N, Goldschmidt E, Boddapati AK, et al. . Shared transcriptional profiles of atypical B cells suggest common drivers of expansion and function in malaria, HIV, and autoimmunity. Sci Adv (2021) 7(22):eabg8384. doi:&#xa0;10.1126/sciadv.abg8384</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abg8384</ArticleId><ArticleId IdType="pmc">PMC8153733</ArticleId><ArticleId IdType="pubmed">34039612</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, Cashman KS, Woodruff MC, Lee FE, Sanz I. Extrafollicular responses in humans and SLE. Immunol Rev (2019) 288(1):136&#x2013;48. doi:&#xa0;10.1111/imr.12741</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12741</ArticleId><ArticleId IdType="pmc">PMC6422038</ArticleId><ArticleId IdType="pubmed">30874345</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu VT, Enghard P, Riemekasten G, Berek C. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol (2007) 179(9):5947&#x2013;57. doi:&#xa0;10.4049/jimmunol.179.9.5947</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.179.9.5947</ArticleId><ArticleId IdType="pubmed">17947668</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rish EY, Amrani Y, Browning MJ. Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF. Rheumatology (2013) 52(7):1190&#x2013;201. doi:&#xa0;10.1093/rheumatology/ket006</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket006</ArticleId><ArticleId IdType="pubmed">23436580</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Guo F, Wang M, Wang T, Wang S, Huang Y, et al. . The effect of TLR9, myD88, and NF-&#x3ba;B p65 in systemic lupus erythematosus. Evidence-Based Complementary Altern Med (2022) 2022:1&#x2013;5. doi:&#xa0;10.1155/2022/6830366</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/6830366</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L, Zhang B, Wu X, Liu R, Fan H, Han L, et al. . Toll-like receptors 7 and 9 regulate the proliferation and differentiation of B cells in systemic lupus erythematosus. Front Immunol (2023) 14:1093208. doi:&#xa0;10.3389/fimmu.2023.1093208</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1093208</ArticleId><ArticleId IdType="pmc">PMC9975558</ArticleId><ArticleId IdType="pubmed">36875095</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan JH, Jiang Y, Mu H, Tang ZQ. Expression of BAFF and BR3 in patients with systemic lupus erythematosus. Braz J Med Biol Res (2016) 49(3):1&#x2013;5. doi:&#xa0;10.1590/1414-431X20154853</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1414-431X20154853</ArticleId><ArticleId IdType="pmc">PMC4763815</ArticleId><ArticleId IdType="pubmed">26840704</ArticleId></ArticleIdList></Reference><Reference><Citation>Smulski CR, Kury P, Seidel LM, Staiger HS, Edinger AK, Willen L, et al. . BAFF- and TACI-dependent processing of BAFFR by ADAM proteases regulates the survival of B cells. Cell Rep (2017) 18(9):2189&#x2013;202. doi:&#xa0;10.1016/j.celrep.2017.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.02.005</ArticleId><ArticleId IdType="pubmed">28249164</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Hoi AY, Harris J, Mackay F, et al. . Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin Trans Immunol (2019) 8(4):1&#x2013;11. doi:&#xa0;10.1002/cti2.1047</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1047</ArticleId><ArticleId IdType="pmc">PMC6475618</ArticleId><ArticleId IdType="pubmed">31024730</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter RH, Zhao H, Liu X, Pelletier M, Chatham W, Kimberly R, et al. . Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheumatism (2005) 52(12):3943&#x2013;54. doi:&#xa0;10.1002/art.21489</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21489</ArticleId><ArticleId IdType="pubmed">16320342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao LD, Li Y, Smith MF, Jr, Wang JS, Zhang W, Tang FL, et al. . Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus (2010) 19(13):1534&#x2013;49. doi:&#xa0;10.1177/0961203310375268</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310375268</ArticleId><ArticleId IdType="pubmed">20974656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Gross JA, Dillon SR, Min JK, Elkon KB. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation. Autoimmunity (2011) 44(2):69&#x2013;81. doi:&#xa0;10.3109/08916934.2010.509122</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916934.2010.509122</ArticleId><ArticleId IdType="pubmed">21250838</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Hase H, Legarda-Addison D, Varughese L, Seed B, Ting AT. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol (2005) 175(5):2814&#x2013;24. doi:&#xa0;10.4049/jimmunol.175.5.2814</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.5.2814</ArticleId><ArticleId IdType="pubmed">16116167</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsov AV, Rubtsova K, Kappler JW, Jacobelli J, Friedman RS, Marrack P. CD11c-expressing B cells are located at the T cell/B cell border in spleen and are potent APCs. J Immunol (2015) 195(1):71&#x2013;9. doi:&#xa0;10.4049/jimmunol.1500055</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1500055</ArticleId><ArticleId IdType="pmc">PMC4475418</ArticleId><ArticleId IdType="pubmed">26034175</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Zhang H, Liu S, Xia F, Kang Z, Zhang Y, et al. . Excessive CD11c+Tbet+ B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus. Proc Natl Acad Sci U S A (2019) 116(37):18550&#x2013;60. doi:&#xa0;10.1073/pnas.1901340116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1901340116</ArticleId><ArticleId IdType="pmc">PMC6744857</ArticleId><ArticleId IdType="pubmed">31451659</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Li J, Zhang YM, Zhang XM, Tao J. Effect of TACI signaling on humoral immunity and autoimmune diseases. J Immunol Res (2015) 2015:1&#x2013;13. doi:&#xa0;10.1155/2015/247426</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/247426</ArticleId><ArticleId IdType="pmc">PMC4381970</ArticleId><ArticleId IdType="pubmed">25866827</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Santamaria R, Xu W, Cols M, Chen K, Puga I, et al. . The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol (2010) 11(9):836&#x2013;45. doi:&#xa0;10.1038/ni.1914</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1914</ArticleId><ArticleId IdType="pmc">PMC3047500</ArticleId><ArticleId IdType="pubmed">20676093</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, et al. . Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol (2001) 2(7):638&#x2013;43. doi:&#xa0;10.1038/89790</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/89790</ArticleId><ArticleId IdType="pubmed">11429549</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji S, Cortes&#xe3;o C, Bram RJ, Platt JL, Cascalho M. TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood (2011) 118(22):5832&#x2013;9. doi:&#xa0;10.1182/blood-2011-05-353961</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-05-353961</ArticleId><ArticleId IdType="pmc">PMC3228499</ArticleId><ArticleId IdType="pubmed">21984806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou X, Xu S, Lam KP. Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival. Proc Natl Acad Sci USA (2012) 109(38):15401&#x2013;6. doi:&#xa0;10.1073/pnas.1200386109</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200386109</ArticleId><ArticleId IdType="pmc">PMC3458353</ArticleId><ArticleId IdType="pubmed">22949644</ArticleId></ArticleIdList></Reference><Reference><Citation>Figgett WA, Fairfax K, Vincent FB, Le Page MA, Katik I, Deliyanti D, et al. . The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death. Immunity (2013) 39(3):573&#x2013;83. doi:&#xa0;10.1016/j.immuni.2013.05.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.05.019</ArticleId><ArticleId IdType="pubmed">24012421</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity (2003) 18(2):279&#x2013;88. doi:&#xa0;10.1016/S1074-7613(03)00025-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(03)00025-6</ArticleId><ArticleId IdType="pubmed">12594954</ArticleId></ArticleIdList></Reference><Reference><Citation>Romberg N, Chamberlain N, Saadoun D, Gentile M, Kinnunen T, Ng YS, et al. . CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest (2013) 123(10):4283&#x2013;93. doi:&#xa0;10.1172/JCI69854</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI69854</ArticleId><ArticleId IdType="pmc">PMC3786721</ArticleId><ArticleId IdType="pubmed">24051380</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakou M, Papadimitraki ED, Fanouriakis A, Bertsias GK, Choulaki C, Goulidaki N, et al. . Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells. Clin Exp Rheumatol (2013) 31:172&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23137515</ArticleId></ArticleIdList></Reference><Reference><Citation>Goenka R, Matthews AH, Zhang B, O'Neill PJ, Scholz JL, Migone TS, et al. . Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med (2014) 211(1):45&#x2013;56. doi:&#xa0;10.1084/jem.20130505</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20130505</ArticleId><ArticleId IdType="pmc">PMC3892970</ArticleId><ArticleId IdType="pubmed">24367004</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann FS, Kuhn PH, Laurent SA, Hauck SM, Berer K, Wendlinger SA, et al. . The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J Immunol (2015) 194(2):542&#x2013;52. doi:&#xa0;10.4049/jimmunol.1402070</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1402070</ArticleId><ArticleId IdType="pmc">PMC4282951</ArticleId><ArticleId IdType="pubmed">25505277</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossen C, Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol (2006) 18(5):263&#x2013;75. doi:&#xa0;10.1016/j.smim.2006.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2006.04.006</ArticleId><ArticleId IdType="pubmed">16914324</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>